– Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 –  – Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small molecule collaboration – – Ended 3Q25 with cash position of $229 million, maintaining runway into 2028 – LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported third quarter 2025 financial and operating results. “Voyager continues to seek out the optimal modalities for each neurotherapeutic target we pursue. During the third quarter, we shared initial preclinical data on our Voyager NeuroShuttle, a nonviral delivery platform with differentiated...

SINGAPORE, Nov. 10, 2025 (GLOBE NEWSWIRE) — Antalpha Platform Holding Company (NASDAQ: ANTA) (“Antalpha” or the “Company”) today announced its unaudited financial results for the quarter ended September 30, 2025. “Antalpha’s revenue grew 62% year over year in the third quarter. Our accelerating revenue growth and margin expansion underscores the scalability of our Prime lending platform, while capturing increasing demand from Bitcoin-mining financing and new lending scenarios, such as digital asset treasury financing,” said Paul Liang, chief financial officer of Antalpha. “A key driver of Antalpha’s growth is our exposure to the burgeoning crypto market, which plays to Antalpha Prime’s strength of leveraging over-collateralization and other risk-management measures to provide institutions liquidity to navigate...

Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 – $200M FY 2026 Revenue, $25M Monthly Revenue or $300M ARR by Year End 2026 IM8 Delivers 60% Gross Margin, 3.9 Months Payback Period, Demonstrating Strong Unit Economics Company to Host Earnings Call Today at 8:30am ET, Releases Inaugural Quarterly Shareholder Letter CHARLOTTE, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) — Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced third quarter 2025 financial results, highlighted by IM8’s trajectory towards $120 million in annualized recurring revenue (“ARR”) in just...

Total Revenues Increased 37% with Record Charging Network Revenue of $56 MillionTotal revenue of $92.3 million in the third quarter, representing an increase of 37% year-over-year. Charging network revenue totaled a record $55.8 million in the third quarter, an increase of 33% year-over-year, representing the 15th consecutive quarter of double-digit year-over-year charging revenue growth. Network throughput reached a record 95 gigawatt-hours (“GWh”) in the third quarter, an increase of 25% year-over-year. Added more than 280 new operational stalls during the third quarter. Ended the third quarter with 4,590 stalls in operation, an increase of 25% year-over-year. $201 million in cash, cash equivalents, and restricted cash. Additional borrowing of $41 million received in October.LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) — EVgo...

Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over Year Nine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up 35% Year-over-Year Positive Outlook for Remainder of 2025 Based on the Company’s Diverse Product Portfolio Supports Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million  Generated $17.9 Million of Cash from Operations During First Nine Months of 2025; as of September 30, 2025, had $72.0 Million of Available Cash Company Continues to Focus on Advancing Business Development Opportunities to Support Continued Long-Term Annual Double-Digit Profitable Growth Interim Futility Analysis of the Pivotal Phase 3 InnovAATe Clinical Trial for the Inhaled AAT Therapy to be Conducted...

ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) — Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results for the third quarter ended September 30, 2025, and provided a business update. Mark Duff, President and Chief Executive Officer (CEO) of the Company, commented, “We are pleased to report improved performance driven by a 45% year-over-year revenue increase and gross margin improvement in our Treatment Segment to 17.3% from 4.5% in the prior year. Higher waste volumes and growing international shipments contributed to improved results, and our treatment backlog continues to build, which we expect will lead to continued improvement through 2026. This growth spans both government and commercial waste streams, further diversifying our customer base and strengthening our overall operating...

TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) — Carbon Streaming Corporation (Cboe CA: NETZ) (OTCQB: OFSTF) (FSE: M2Q) (“Carbon Streaming” or the “Company”) today reported its financial results for the three and nine months ended September 30, 2025. All figures are expressed in United States dollars, unless otherwise indicated. Carbon Streaming Chief Executive Officer Marin Katusa stated: “In the third quarter of 2025, Carbon Streaming continued to strengthen its financial position and focus on maximizing value from its existing portfolio. During the quarter, we achieved positive operating cash flow, reflecting the success of our cost reduction initiatives and continued progress in generating cash from our stream and royalty agreements. We also successfully implemented the terms of the InfiniteEARTH settlement, delivering cash proceeds...

– $169.7 million revenue, up 173.6% year-over-year– $43.0 million adjusted EBITDA, up from negative $7.9 million last year– Expanding and accelerating AI strategy across multiple initiatives– Achieved 41.2 EH/s of self-mining at the end of October, 2025– Commenced SEALMINER A3 mass production– Early SEAL04 samples have demonstrated 6-7 J/TH power efficiency at the chip level under low-voltage, ultra-power saving mode SINGAPORE, Nov. 10, 2025 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for Bitcoin mining and AI cloud, today released its unaudited financial results for the third quarter ended September 30, 2025. Q3 2025 Financial HighlightsAll amounts compared to Q3 2024 unless otherwise notedTotal revenue was US$169.7...

Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients Initial TN-201 Cohort 2 Data Demonstrated Early Dose Responsive Increases in TN-201 Transduction and MyBP-C Protein Expression Completed Dosing in Cohort 2 of RIDGE™-1 Trial of TN-401 for PKP2-associated ARVC; Cohort 1 Data On Track for Fourth Quarter Company Presentation Tenaya Management to Review New MyPEAK-1 Data on Webcast Call for Analysts and Investors Today at 8:00 a.m. EST SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart...

SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development Candidate SEP-631 (MRGPRX2 NAM) Phase 1 Clinical Trial in Healthy Volunteers Ongoing Robust Financial Position of $561.6 Million Expected to Support Operations at Least into 2029 SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted key business updates and upcoming milestones and reported financial results for the quarter ended September 30, 2025.   “In the third quarter, we made meaningful progress across our portfolio, highlighted by the selection of SEP-479 as our next-generation PTH1R agonist development candidate for hypoparathyroidism and the initiation of our Phase 1 clinical trial for SEP-631...